Category Archives: Central and Eastern Europe

REPLICOR’S NEW PHASE II TRIAL CONDUCTED BY CLINICAL ACCELERATOR PRODUCES EXCITING CLINICAL DATA FOR THEIR NUCLEIC ACID POLYMER (NAP) DRUG REP 2139-CA FOR PATIENTS WITH HBV / HDV CO-INFECTION.

In December last year a Clinical Accelerator post (1) reported that recruitment was underway in Moldova for an interesting Phase II trial of Replicor’s novel nucleic acid polymer (NAP), REP 2139-Ca, in combination with the immunotherapeutic agent, pegylated interferon alfa-2a … Continue reading

Posted in Central and Eastern Europe, Clinical Accelerator | Leave a comment

IQPC finally recognizes the value of Eastern Europe for clinical trials

You don’t say! Packed with eager, treatment naive participants, and short of the many transportation complexities faced in little established research sites, Eastern Europe is becoming increasingly recognised as among the best places to conduct a clinical trial. The surprise … Continue reading

Posted in Central and Eastern Europe | Leave a comment

Completion of D-Pharm’s Phase II trial for stroke patients in Ukraine

Clinical Accelerator is pleased to announce the timely completion of an interesting trial it has been conducting for D-Pharm in patients with ischaemic stroke at the State Medical Preventive Institution “Central Clinical Hospital of Ukrzaliznytsia”, Kharkov, Ukraine (1). This study … Continue reading

Posted in Central and Eastern Europe, Clinical Accelerator | Leave a comment

Clinical trials in Poland

At Clinical Accelerator we conduct many of our trials in Central and Eastern Europe, and it’s important to us that we monitor the latest data coming for our countries of operation. We’re pleased to see that, based on recent statistics, … Continue reading

Posted in Central and Eastern Europe | Leave a comment

FDA inspections produce solid evidence of high quality clinical trial data originating in Central and Eastern Europe

Clinical Accelerator is a clinical CRO with a special focus on Central and Eastern Europe currently operating in 11 countries of the region: Belarus, Estonia, Georgia, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russian Federation and Ukraine (listed alphabetically).  The quality … Continue reading

Posted in Central and Eastern Europe, Clinical Accelerator, FDA, Regulations | Leave a comment

How to improve and retain the participation of minorities in clinical trials – lessons learned from the Maryland Regional Community Network Program

Challenges in recruiting patients from minorities Successfully recruiting ethnic minorities into clinical trials is a major challenge for healthcare professionals. There are obvious benefits to the individual and their community, and to the integrity of scientific research through the diversity … Continue reading

Posted in Central and Eastern Europe, Patient Enrolment, Social Media | Leave a comment

Creating culturally appropriate enrolment approaches for education and retention of patients in clinical trials in Eastern Europe

Difficulties in recruiting patients One of the biggest problems in conducting clinical trials successfully is patient recruitment. Another challenge is assuring diversity in clinical trials enrolment which is essential for eliminating health disparities as low enrollment and participation of racial/ethnic minorities … Continue reading

Posted in Central and Eastern Europe, Patient Enrolment | Leave a comment

A clinical trial completed within six months: Making a hard task possible

Interview with Paul Duxbury  Managing Director, Nasaleze International Ltd What is your experience with clinical trials? We’ve been involved since 2003 when we formed the company. We realised that, if we wanted to be taken seriously, we needed evidence-based trial work. … Continue reading

Posted in Central and Eastern Europe, Clinical Accelerator, Patient Enrolment | Tagged | Leave a comment